Acompanhe as Notícias da Recifes

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published in the Journal of Virology, suggest that the drugs may offer benefits to another patient popula